Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | APP | P05067 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970571 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP3A4APPMEN1KMT2A | |
| SCHEMBL970017 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP3A4APPMEN1KMT2A | |
| SCHEMBL466186 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP3A4APPMEN1KMT2A | |
| SCHEMBL19912050 | 0.89 | CYP3A4 (0.56) | SMN1; SMN2CYP3A4APPMEN1KMT2A | |
| SCHEMBL5473974 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP3A4APPMEN1KMT2A | |
| SCHEMBL5468192 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP3A4APPMEN1KMT2A | |
| SCHEMBL5457352 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP3A4APPMEN1KMT2A | |
| SCHEMBL5459507 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP3A4APPMEN1KMT2A | |
| SCHEMBL5462324 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP3A4APPMEN1KMT2A | |
| SCHEMBL270793 | 0.89 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP3A4APPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
| US-9815784-B2 | CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2017-11-14 | — | — | US | disclosed |
| US-9815784-B2 | CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2017-11-14 | — | — | US | disclosed |
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-09-28 | — | — | US | disclosed |
| US-9629924-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2017-04-25 | — | — | US | disclosed |
| US-9629924-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2017-04-25 | — | — | US | disclosed |
| US-8889868-B2 | CC-1065 analogs and their conjugates | SYNTARGA BV (NL) | 2014-11-18 | — | — | US | disclosed |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | BYONDIS B.V. (NL) | 2013-08-29 | — | — | US | disclosed |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | BYONDIS B.V. (NL) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | SMN1; SMN2 645/4885CYP3A4 4379/4885APP 4829/4885 |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | SMN1; SMN2 645/4885CYP3A4 4379/4885APP 4829/4885 |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | PCNA, CDC5L, TOP1 | SMN1; SMN2 590/4885CYP3A4 3774/4885APP 4837/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | SMN1; SMN2 645/4885CYP3A4 4379/4885APP 4829/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | SMN1; SMN2 645/4885CYP3A4 4379/4885APP 4829/4885 |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | PCNA, DCLRE1A, CDC5L | SMN1; SMN2 645/4885CYP3A4 4379/4885APP 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.